

# 13-cis retinoic acid as continuation therapy in children with advanced neuroblastoma in complete or good partial remission

<b>Submission date</b> 01/07/2001	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 01/07/2001	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 01/02/2012	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr - -

### Contact details

UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

NB8904

# Study information

## Scientific Title

## Study objectives

Not provided at time of registration

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Not Specified

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Solid tumour of childhood

## Interventions

Initial therapy followed by either:

1. Continuation Therapy: Thirteen-cis-retinoic acid
2. Control: Placebo

## Intervention Type

Other

## Phase

Not Specified

## Primary outcome measure

Not provided at time of registration

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/03/1995

**Completion date**

30/03/1997

## Eligibility

**Key inclusion criteria**

1. Stage III or IV neuroblastoma
2. In complete or good partial remission following initial therapy

**Participant type(s)**

Patient

**Age group**

Child

**Sex**

Not Specified

**Target number of participants**

Not provided at time of registration

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/03/1995

**Date of final enrolment**

30/03/1997

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

# Sponsor information

## Organisation

Cancer Research UK (CRUK) (UK)

## Sponsor details

PO Box 123  
Lincoln's Inn Fields  
London  
United Kingdom  
WC2A 3PX  
+44 (0)207 317 5186  
kate.law@cancer.org.uk

## Sponsor type

Charity

## Website

<http://www.cancer.org.uk>

## ROR

<https://ror.org/054225q67>

# Funder(s)

## Funder type

Charity

## Funder Name

Cancer Research UK

## Alternative Name(s)

CR\_UK, Cancer Research UK - London, CRUK

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

United Kingdom

# Results and Publications

Publication and dissemination plan  
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary  
Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/11/2000		Yes	No